BCOR Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal population derived from the A-549 human lung adenocarcinoma cell line, engineered for functional disruption of the BCOR gene. This knockout model provides a valuable tool for investigating BCOR-dependent transcriptional regulation and epigenetic silencing mechanisms. The polyclonal knockout format offers a heterogeneous pool of cells with targeted gene disruption, enabling researchers to study loss-of-function phenotypes without clonal selection biases.
The A-549 cell line, originally established from a 58-year-old Caucasian male with lung adenocarcinoma, serves as a widely utilized model of alveolar basal epithelial cells. These cells retain key characteristics of lung adenocarcinoma, including epithelial morphology and oncogenic signaling alterations, making them suitable for studying lung cancer biology, drug responses, and tumor progression. The A-549 background provides a relevant epithelial context for examining BCOR function in non-small cell lung cancer.
BCOR (BCL6 corepressor) functions as a transcriptional corepressor that mediates gene silencing by assembling a non-canonical Polycomb repressive complex 1 (PRC1.1) with components such as PCGF1, RING1, RYBP, and KDM2B. This complex catalyzes histone H2A monoubiquitination at lysine 119 (H2AK119ub1), leading to chromatin compaction and repression of target loci. BCOR primarily acts downstream of the BCL6 transcription factor and is regulated by Notch intracellular domain (NICD) signaling. It transcriptionally modulates cell cycle regulators, DNA damage response genes, and differentiation-associated genes, thus influencing proliferation and differentiation pathways.
In the A-549 lung adenocarcinoma background, disruption of BCOR is expected to impact BCOR-dependent transcriptional programs associated with tumor suppression or oncogenesis. BCOR mutations and alterations have been implicated in various malignancies, including acute myeloid leukemia, myelodysplastic syndromes, and clear cell sarcoma of the kidney. In lung adenocarcinoma, BCOR may interact with BCL6-mediated pathways to regulate genes controlling cell cycle progression and epithelial differentiation. Thus, this knockout model enables dissection of BCOR’s role in lung cancer cell proliferation, survival, and response to therapeutic agents.
Researchers can employ BCOR Knockout A-549 Polyclonal Cells in a range of functional genomics and cancer biology studies. Representative assays include western blotting to confirm BCOR loss and monitor H2AK119ub1 levels, RT-qPCR to assess target gene expression, and ChIP-qPCR to evaluate H2AK119ub1 enrichment at specific promoters. Transcriptomic analysis via RNA-seq can reveal BCOR-dependent gene regulatory networks. Functional assays such as cell proliferation, colony formation, migration, and invasion assays allow characterization of phenotypic consequences in lung adenocarcinoma models. Flow cytometry enables cell cycle distribution analysis. For further information or to request technical support, please contact Ascent Research.
